Company intelligence / Profile preview
Biosceptre
Cambridge, England, United Kingdombiosceptre.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Biosceptre has completed Phase 1 trials for its topical antibody therapy in basal cell carcinoma and initiated a Phase 1 trial for its peptide vaccine BIL06v in advanced solid tumors. Early results indicate safety and tolerability of the topical therapy. The company’s CAR-T program targeting nfP2X7 is in preclinical development[5][8][10].
- Therapeutic areas
- OncologyHematology
- Modalities
- CAR-T cellsmonoclonal antibodies (mAbs)domain antibodies (dAb)peptide vaccines
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Carina Biotech – collaboration on development of the nfP2X7-targeted CAR-T program; Carina granted exclusive rights to IP related to this technology to Biosceptre [6].
Beyond the preview
Go deeper on Biosceptre.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Biosceptre.